Valuation: Camurus AB

Market Cap 33.24B 3.44B 3.01B 2.78B 2.57B 4.87B 328B 4.96B 13.03B 161B 12.91B 12.64B 559B P/E 2026 *
37.1x
P/E 2027 * 20.5x
Enterprise Value 28.79B 2.98B 2.61B 2.4B 2.22B 4.22B 284B 4.29B 11.28B 140B 11.19B 10.94B 484B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 6.84x
Free-Float
64.67%
Yield 2026 *
-
Yield 2027 * -
1 day-1.66%
1 week-1.66%
Current month-1.66%
1 month+3.45%
3 months+9.09%
6 months-10.58%
Current year-10.61%
1 week 60
Extreme 60
60
1 month 54
Extreme 54
61.01
Current year 54
Extreme 54
71
1 year 54
Extreme 54
71
3 years 46.15
Extreme 46.15
71.07
5 years 21.81
Extreme 21.81
71.07
10 years 7.48
Extreme 7.48
71.07
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2003
Director of Finance/CFO 57 01/07/2025
Chief Tech/Sci/R&D Officer 58 01/01/2025
Director TitleAgeSince
Director/Board Member 63 01/01/2002
Chairman 77 01/01/2015
Director/Board Member 61 07/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%-1.66% - - 3.41B
-0.02%+0.16%+54.51%+168.31% 1,084B
-1.45%-1.16%+66.36%+62.99% 634B
-1.45%-4.50%+30.79%+85.37% 447B
+0.18%-1.76%+29.04%+26.48% 330B
-6.22%-8.14%+28.87%+31.18% 295B
-1.27%-2.91%+27.42%+44.91% 285B
-0.93%-3.57%-27.74%-39.70% 218B
-1.26%-3.03%+22.36%+61.45% 199B
-1.33%+1.93%+18.16%+76.77% 169B
Average -1.54%+2.52%+27.75%+57.53% 406.65B
Weighted average by Cap. -1.21%+2.48%+38.88%+84.09%

Financials

2026 *2027 *
Net sales 2.8B 290M 253M 234M 216M 410M 27.65B 417M 1.1B 13.58B 1.09B 1.06B 47.04B 4.02B 416M 364M 336M 311M 590M 39.74B 600M 1.58B 19.51B 1.56B 1.53B 67.59B
Net income 890M 92.07M 80.55M 74.28M 68.72M 130M 8.79B 133M 349M 4.32B 346M 338M 14.95B 1.61B 167M 146M 135M 125M 237M 15.94B 240M 632M 7.83B 627M 613M 27.11B
Net Debt -4.45B -460M -403M -371M -344M -652M -43.95B -663M -1.74B -21.58B -1.73B -1.69B -74.75B -5.74B -594M -519M -479M -443M -841M -56.68B -855M -2.25B -27.83B -2.23B -2.18B -96.41B
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
308
Date Price Change Volume
06/07/26 $60.00 -1.66% 1,500
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
558.50SEK
Average target price
769.50SEK
Spread / Average Target
+37.78%

Quarterly revenue - Rate of surprise